Market Research Logo

Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report

Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report

Stem cell therapy for osteoarthritis: An insight

The stem cell therapy for osteoarthritis pipeline analysis report includes ongoing clinical and non-clinical trends in the global stem cell therapy for osteoarthritis. Majority of the pipeline therapeutics are in early stages of development. There is no cure for the disease, but treatments are available to manage the symptoms. A long-lasting and less-frequent dose can impact overall osteoarthritis market.

The global osteoarthritis market is expected to grow at a CAGR of 8.55% over the period of 2014-2019. The expected growth is because of increasing awareness of osteoarthritis and increasing diagnosis rates, rising older population, and increasing cases of obesity. Osteoarthritis is directly related to obesity, with approximately 37% of osteoarthritis patients suffering from obesity.

Covered in this report

The report covers the present scenario and the growth prospects of the stem cell therapy for osteoarthritis. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.

Major companies

  • Mesoblast
  • Regeneus
  • U.S. Stem Cell
  • Anterogen
  • Asterias Biotherapeutics
  • Key questions answered in this report
    • How will the market evolve during the forecast period?
    • What are the major parameters impacting the market?
    • What are the key market trends?
    • What are the challenges to market growth?
    • Who are the key companies in this market space?


    Press Release

    Technavio Announces the Publication of its Research Report - Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report

    Technavio recognizes the following companies in the stem cell therapy for osteoarthritis: Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics.

    The Stem cell therapy for osteoarthritis - A pipeline analysis report, 2017” provides comprehensive insights about pipeline molecules across this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under osteoarthritis stem cell therapy.

    This report provides information on the therapeutic development based on the stem cell therapy for osteoarthritis dealing with all the pipeline drugs; comparative analysis at various stages covering Phase III, Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the information of companies that are involved in the development of pipeline products. It also highlights the dormant products.

    Degenerative joint disease and “wear and tear” arthritis are some of the synonyms used for osteoarthritis. It is the most common chronic condition of the joints, which features the breakdown and eventual loss of the cartilage of one or more joints. Osteoarthritis occurs mostly in knees; however, it can affect any joints such as hips, lower back, neck, small joints of the fingers, and the bases of the thumb and big toe. Osteoarthritis can occur in people of all ages and sex, but it is most common in people older than 65 years. The basic difference between rheumatoid arthritis and osteoarthritis is that the rheumatoid arthritis is an autoimmune disease characterized by an overactive, misdirected immune system while osteoarthritis is a disease of the cartilage of joints, and it is not a systemic disease or an autoimmune disease.

    Companies Mentioned

    Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics.

    • Executive summary
    • Scope of the report
    • Research Methodology
    • Stem cell therapy for osteoarthritis: An insight
      • Introduction
    • Major regulatory authorities
      • US
        • Table Drug approval process by US FDA
      • Europe
      • Japan
      • Australia
      • China
    • Pipeline landscape
      • Table Pipeline molecules by vendors
      • Table Pipeline landscape
    • Comparative analysis
      • Table Pipeline molecules in different developmental stages 2017
      • Table Percentage of pipeline molecules in different developmental stages 2017
      • Late-stage molecule (Phase III)
        • Table Overview: GID SVF
        • Table Clinical trials description of autologous adipose-derived SVF cells
      • Mid-stage molecules (Phase II and Phase I/II)
        • Table Overview: ReJoin
        • Table Clinical trials description of ReJoin (mesenchymal progenitor cells)
        • Table Overview: Autologous regenerative cell therapy
        • Table Clinical trials description of autologous regenerative cell therapy
        • Table Overview: MSB-CAR001
        • Table Clinical trials description of MSB-CAR001
        • Table Overview: Stempeucel
        • Table Clinical trials description of Stempeucel osteoarthritis
        • Table Overview: Stemchymal
        • Table Clinical trials description of Stemchymal
        • Table Overview: Elixcyte
        • Table Clinical trials description of Elixcyte
      • Early-stage molecules (Phase I and pre-clinical)
        • Table Overview: AlloJoin
        • Table Clinical trials description of AlloJoin
        • Table Overview: Human Umbilical Cord MSCs
        • Table Clinical trials description of Human umbilical cord MSCs
        • Table Overview: Progenza
        • Table Clinical trials description of Progenza
        • Table Overview: Adipose-derived stromal cells
        • Table Clinical trials description of Adipose-derived stromal cells
        • Table Overview: ALLO-ASC-OA
        • Table Overview: GRNCHND1
        • Table Overview: Stem cell therapy for osteoarthritis
        • Table Overview: Allogeneic mesenchymal stem cell candidate
      • Inactive molecules
        • Table Inactive molecules 2017
    • Indication analysis
      • Table Analysis by indication
    • Therapeutic assessment by therapy
      • Therapeutic assessment based on therapy
        • Table Assessment of stem cell therapy for osteoarthritis by therapy
    • Therapeutic assessment by RoA
      • Therapeutic assessment based on RoA
        • Table Assessment of stem cell therapy for osteoarthritis by RoA
    • Therapeutic assessment by stage and RoA
      • Therapeutic assessment based on RoA in various stages of development
        • Table Assessment of stem cell therapy for osteoarthritis by stage and RoA
    • Key companies
      • Active companies: Category and parameters
        • Table Active companies: Category and parameters 2017
        • Table Segmentation of companies 2017
        • Table Overview: Anterogen 2017
        • Table Overview: Asterias Biotherapeutics 2017
        • Table Overview: Cellular Biomedicine Group 2017
        • Table Overview: Mesoblast 2017
        • Table Overview: Regeneus 2017
        • Table Overview: OrthoCyte* 2017
        • Table Overview: Shenzhen Hornetcorn Bio-technology 2017
        • Table Overview: Steminent Biotherapeutics 2017
        • Table Overview: Stempeutics Research 2017
        • Table Overview: The GID Group 2017
        • Table Overview: UnicoCell Biomed 2017
        • Table Overview: U.S. Stem Cell 2017
        • Table Overview: VivaTech International 2017
        • Table Overview: Xintela 2017
    • Appendix
      • List of abbreviations
    • Explore Technavio

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report